In this free expert panel discussion, hear from thought-leaders from across industry and academia on the transformative power of at-home and in-clinic innovations in central nervous system (CNS) clinical trials. Attendees will learn how digital biomarkers have the potential to transform CNS clinical trials much the same way that next-generation sequencing has transformed oncology, enabling personalized treatment. The featured panelists will discuss the power of longitudinal EEG data synchronized with behavioral assessment data, and how this can enable leaner trial designs and accelerate clinical development of CNS therapies.

TORONTO, Aug. 29, 2025 /PRNewswire/ -- As Alzheimer's clinical trials continue to evolve, the panel will discuss the latest advances in real-world longitudinal data collection, featuring key findings from a first-in-class study (CNS-101) presented at the recent Alzheimer's Association International Conference (AAIC) by Cumulus Neuroscience.

Expert panelists:

• Dr. Ruth McKernan, FMEdSci CBE, Operating Partner, SV Health Investors, CEO, Draig Therapeutics and Chair, Cumulus Neuroscience
• Professor James Rowe, BA BMBCh FRCP PhD, Director of Cambridge Centre for Frontotemporal Dementia and Related Disorders, Department of Clinical Neurosciences, University of Cambridge and Chief Investigator for CNS-101
• Bryan J. Hansen, PhD, Pharma Neuroscientist, Technologist, and Innovator
• Brian Murphy, PhD, Co-Founder and CSO, Cumulus Neuroscience

CNS-101 was designed and executed in collaboration with 10 top pharma companies utilizing the NeuLogiq® Platform which combines multimodal assessments, passive EEG and naturalistic language markers to track Alzheimer's disease progression. Importantly, this platform has been optimized for use in-clinic or at home for longitudinal data capture. The study demonstrated that repeated at-home measurements provide greater sensitivity and statistical power than the widely used Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog 13), enabling more accurate and scalable monitoring of dementia progression. Additionally, the study confirmed that at-home endpoints associated with Alzheimer's pathology (phosphorylated tau 217) outperformed traditional benchmark measures over time.

Digital endpoints address the key limitations associated with "snapshot in time" clinic-only measures by enabling longitudinal, real-world monitoring that accurately reflects patient disease trajectory and cognitive performance in day-to-day life, where it matters the most.

The panelists will explore strategies for improving clinical trial designs for Alzheimer's disease, emphasizing the integration of digital biomarkers to enhance sensitivity, objectivity, scalability and patient-centricity. They will discuss how digital endpoints collected in clinic and at home can provide greater discriminative power than standard measurement tools used in CNS clinical studies today. Importantly, they will discuss how these findings can be translated across a broad range of CNS disease states.

This panel discussion aims to illustrate how the evolution of remote, real-world data collection can enable leaner trial designs, accelerate clinical development of effective CNS therapies and ultimately improve the lives of millions of people affected by Alzheimer's disease worldwide.

Register for this virtual panel discussion which will take place on Wednesday, September 17, 2025, at 12pm EDT (9am PDT) to learn how digital endpoints are transforming Alzheimer's disease clinical trials

For more information, or to register for this event, visit Innovations in Alzheimer's Disease Clinical Trials: Digital Endpoints.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks, visit www.xtalks.com
For information about hosting a webinar, visit www.xtalks.com/why-host-a-webinar/

Contact:
Vera Kovacevic
Tel: +1 (416) 977-6555 x371
Email: vkovacevic@xtalks.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/expert-panel-to-discuss-innovations-in-alzheimers-disease-clinical-trials-302542041.html

SOURCE Xtalks